Kling Bio has announced a new collaboration and licence option agreement with Sanofi to accelerate the discovery of neutralising antibodies using its proprietary B cell platform, Kling-Select.

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma  Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...

PARIS (FRANCE) AND TARRYTOWN, NY - December 10, 2019 – Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced their intent to simplify their antibody collaboration for Kevzara ...

Using patient-derived B cells, Kling-Select facilitates the rapid detection of new antibodies and preserved viral epitopes.

Terms of the Collaboration As previously announced, under the terms of the collaboration agreement, for each of the three Sanofi designated immunology/inflammation targets, IGM will lead research ...

John Reed, MD,Ph.D. Global Head of Research and Development for Sanofi“The collaboration with Blackstone will accelerate our ability to offer patients a subcutaneous anti-CD38 antibody therapy ...

Sanofi will lead commercialisation of any successful product from the collaboration. U.S. profits will be split equally, while elsewhere Sanofi will take a share of 55 to 65 percent.

Regeneron will also accelerate reimbursement of the development balance associated with Regeneron and Sanofi’s separate Antibody Collaboration. Regeneron will increase from 10% to 20% the share ...

Within in the Sanofi antibody collaboration, LDL cholesterol reduction drug Praluent has seen a slow launch trajectory because of payer restrictions, but we think U.S. sales growth can rebound ...

Within the Sanofi antibody collaboration, LDL cholesterol reduction drug Praluent has seen a slow launch trajectory because of payer restrictions, but we think U.S. sales growth can rebound, now ...

MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...